Data Sheet (Cat.No.TWA2417)

TargetMol

Sodium taurocholate

Chemical Properties



CAS No. : 145-42-6

Formula: C26H44NO7S.Na

Molecular Weight: 537.69

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Sodium taurocholate is a biologically active compound that can inhibit bile duct injury induced by hepatic artery ligation by upregulating VEGF-A expression. It also exhibits immunomodulatory effects and can be used to induce pancreatitis models.
Targets(IC50)	Others

Solubility Information

Solubility	H2O: 53.76 mg/mL (99.98 mM),Sonication is recommended. DMSO: 176.4 mg/mL (328.07 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2.5 mg/mL (4.65 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8598 mL	9.299 mL	18.5981 mL
5 mM	0.372 mL	1.8598 mL	3.7196 mL
10 mM	0.186 mL	0.9299 mL	1.8598 mL
50 mM	0.0372 mL	0.186 mL	0.372 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Khatun, Z., Nurunnabi, M., Cho, K., Byun, Y., Bae, Y., & Lee, Y. (2014). Oral absorption mechanism and anti-angiogenesis effect of taurocholic acid-linked heparin-docetaxel conjugates. Journal Of Controlled Release, 177, 64-73. doi: 10.1016/j.jconrel.2013.12.034

Mathavan, S., Mikov, M., Golocorbin-Kon, S., & Al-Salami, H. (2017). Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects. European Journal Of Pharmaceutical Sciences, 106, 1-9. doi: 10.12016/j.ejps.2017.05.041